Already a subscriber? Make sure to log into your account before viewing this content. You can access your account by hitting the “login” button on the top right corner. Still unable to see the content after signing in? Make sure your card on file is up-to-date.
AstraZeneca has agreed to a $425 million settlement regarding claims that its heartburn medications Nexium and Prilosec led to kidney injuries in consumers.
The pharmaceutical giant stated that while they find the claims “are without merit,” the settlement allows them to avoid ongoing litigation costs. AstraZeneca emphasized that they have admitted no wrongdoing in the agreement.
The lawsuits, which were brought forward by approximately 11,000 claimants, alleged that the drugs could induce kidney injuries, potentially leading to chronic kidney disease and subsequent end-stage renal disease. They also contended that the risks associated with these proton-pump inhibitor (PPI) medications were inadequately researched and undisclosed.
This new settlement follows previous agreements totaling $108.5 million with companies including GlaxoSmithKline, Procter & Gamble, and Pfizer.